Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-08-28
2007-08-28
Siew, Jeffrey (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S185100, C424S190100, C424S184100, C530S300000, C530S324000
Reexamination Certificate
active
10638006
ABSTRACT:
The invention relates to improved methods of producing and recovering sporulation-deficientB. anthracismutant stains, and for producing and recovering recombinantB. anthracisprotective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of,B. anthracisbacterial infections and which are useful to prevent and/or treat illnesses caused byB. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.
REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 5840312 (1998-11-01), Mock et al.
patent: 6267966 (2001-07-01), Baillie
Thomas E. Creighton, Proteins: Structures and Molecular Properties, 1984, (pp. 314-315).
Thomas E. Creighton, in his book “Protein Structure: A Practical Approach, 1989; pp. 184-186”.
Nosoh, Y. et al in “Protein Stability and Stabilization through Protein Engineering, 1991” (chapter 7, p. 197, second paragraph.
Ellis (Vaccines, W.B. Saunders Company, Chapter 29, 1988, pp. 568-574).
Boslego et al (Vaccines and Immunotherapy, 1991, Chapter 17).
Klimpel et al (Proc. Natl. Acad. Sci. USA, vol. 89, Nov. 1992).
Singh et al (The Journal of Biological Chemistry, vol. 364, No. 32, Nov. 15, 1989).
Benson et al (Biochemistry 1998, 37, 3941-3948).
Singh et al (The Journal of Biological Chemistry, vol. 269, No. 46, Nov. 18, p . 29039-29046, 1994).
Wild et al, Nature Biotechnology, pp. 1-2.
Wang et al, Human Antibodies 13, 2004, 105-110.
Flick-Smith et al, Infection and Immunity, Mar. 2002, p. 1653-1656.
Singh et al, Infection and Immunity, Jul. 1998, p. 3447-3448.
Vanughese et al, Infection and Immunity, Apr. 1999, p. 1860-1865.
Benson et al, Biochemistry, 1998, 37, p. 3941-3948.
Khanna et al, FEMS Microbiol. Letter. 2001, May 15; 199(1):27-31.
Pezaed et al, Infection and Immunity, Apr. 1995, p. 1369-1372.
Baillie et al., “The expression of the protective antigen ofBacillus anthracisinBacillus subtilis,” J. Appl. Microbiol. 84:741-746, 1998.
Coulson et al., “Bacillus anthracisprotective antigen expressed inSalmonella typhimuriumSL3261 affords protection against anthrax spore challenge,”Vaccine12:1395-1401, 1994.
Farchaus et al., “Purification and characterization of the major surface array protein from the avirulentBacillus anthracisDelta Sterne-1,”J. Bacteriol. 177:2481-2489, 1995.
Farchaus et al., “Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain ofBacillus anthracis,” Appl. Environ. Microbiol. 64:982-991, 1998.
Fouet et al., “Bacillus anthracissurface: capsule and S-layer,”J. Appl. Microbiol. 87:251-255, 1999.
Gladstone, “Immunity to anthrax: protective antigen present in cell-free culture filtrates,”Br. J. Exp. Pathol. 27:394-418, 1946.
Gupta et al., “Expression and purification of the recombinant protective antigen ofBacillus anthracis,” Protein Expr.Purif. 16:369-376, 1999.
Hemila et al., “Improving the production ofE. colibeta-lactamase inBacillus subtilis: the effect of glucose, pH and temperature on the production level,”J. Biotechnol. 26:245-56, 1992.
Iacono-Connors et al., “Expression of theBacillus anthracisprotective antigen gene by baculovirus and vaccinia virus recombinants,”Infect. Immun. 58:366-372, 1990.
Ivins et al., “Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques,”Vaccine16:1141-1148, 1998.
Ivins and Welkos, “Cloning and expression of theBacillus anthracisprotective antigen gene inBacillus subtilis,” Infect. Immun.. 54-537-542, 1986.
Keppie et al., “The chemical basis of the virulence ofBacillus anthracis,IX, Its aggressins and their mode of action,”Br. J. Exp. Pathol. 44:446-453, 1963.
Leppla, “Production and purification of anthrax toxin,”Methods Enzymol. 165:103-116, 1988.
Leppla, “The anthrax toxin complex,” In: Sourcebook of bacterial toxins (Alouf and Freer, eds.), pp. 277-302, Academic Press, Inc., San Diego, CA.
Leppla, “Anthrax toxins,” In: Bacterial toxins and virulence factors in disease, Handbook of natural toxins (Moss et al., eds.), pp. 543-572, Dekker, New York.
Little et al., “Passive protection by polyclonal antibodies againstBacillus anthracisinfection in guinea pigs,”Infect. Immun. 65:5171-5175, 1997.
Miller et al., “Production and purification of recombinant protective antigen and protective efficacy againstBacillus anthracis,” Lett. Appl. Microbiol. 26:56-60, 1998.
Park and Leppla, “ Optimized production and purification ofBacillus anthracislethal factor,”Protein Expression and Purification18:293-302, 2000.
Puziss et al., “Large-scale production of protective antigen ofBacillus anthracisanaerobic cultures,”Appl. Microbiol. 11:330-334, 1963.
Reuveny et al., “Search for correlates of protective immunity conferred by anthrax vaccine,”Infect. Immun. 69:2888-2893, 2001.
Sharma et al., Expression and purification of anthrax toxin protective antigen fromEscherichia coli, Protein Expr. Purif. 7:33-38, 1996.
Simonen and Palva, “Protein secretion inBacillusspecies,”Microbiol. Rev. 57:109-137, 1993.
Singh et al., “A deleted variant ofBacillus anthracisprotective antigen is non-toxic and blocks anthrax toxin action in vivo,”J. Biol. Chem. 264:19103-19107, 1989.
Singh et al., “Study of immunization against anthrax with the purified recombinant protective antigen ofBacillus anthracis,” Infect. Immun. 66:3447-3448, 1998.
Singh et al., “The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor,”J. Biol. Chem. 269:29039-29046, 1994.
Thorne, “Genetics ofBacillus anthracis,” In: Microbiology (Leive et al.eds), pp. 56-62, American Society for Microbiology, Washington, D.C., 1985.
Turnbull, “Anthrax vaccines: past, present, and future,”Vaccine9:533-539, 1991.
Vodkin and Leppla, “Cloning of the protective antigen gene ofBacillus anthracis,” Cell34:693-697, 1983.
Welkos et al., “Sequence and analysis of the DNA encoding protective antigen ofBacillus anthracis,” Gene69:287-300, 1988.
Leppla Stephen H.
Robbins John B.
Rosovitz Mary Jo
Schneerson Rachel
Ford Vanessa L.
Klarquist & Sparkman, LLP
Siew Jeffrey
The United States of America as represented by the Secretary of
LandOfFree
Recombinant modified Bacillus anthracis protective antigen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant modified Bacillus anthracis protective antigen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant modified Bacillus anthracis protective antigen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3840908